Show simple item record

dc.contributor.supervisor Jassal, Davinder S. (Physiology); Singal, Pawan K. (Physiology) en
dc.contributor.author Walker, Jonathan Robert
dc.date.accessioned 2010-09-24T21:51:18Z
dc.date.available 2010-09-24T21:51:18Z
dc.date.issued 2010-09-24T21:51:18Z
dc.identifier.citation Walker J, Bhullar N, Fallah-Rad N, et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 2010;28:3429-36. en
dc.identifier.citation Walker JR, Singal PK, Jassal DS. The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure. Exp Clin Cardiol 2009;14:e62- 7. en
dc.identifier.uri http://hdl.handle.net/1993/4252
dc.description.abstract Background: In breast cancer patients, the administration of Trastuzumab and Doxorubicin is associated with an increased risk of cardiotoxicity. The aim of the study was to determine if the antioxidant probucol would be useful in attenuating this drug induced cardiotoxicity. Methods: In an acute murine model of chemotherapy induced cardiomyopathy, wild-type C57Bl/6 mice received one of the following regimens: (1) control; (2) doxorubicin; (3) trastuzumab; (4) dox+trastuzumab; (5) probucol; (6) probucol +dox; (7) probucol+trastuzumab; (8) probucol+dox+trastuzumab. Serial murine echocardiography with tissue Doppler imaging was performed daily. Histological and biochemical studies were conducted at day 10 of the experiment. Results: Mice treated with prophylactic probucol demonstrated minimal cardiotoxicity compared with those treated with doxorubicin+trastuzumab. Survival rate was only 27% at day 3 of the experiment in the doxorubicin+trastuzumab group compared to 82% of mice receiving probucol+ doxorubicin+trastuzumab. Survival, apoptosis and histological remodeling were preserved in mice prophylactically treated with probucol following the administration of trastuzumab+doxorubicin. Conclusion: The synergistic cardiotoxicity of trastuzumab plus doxorubicin is attenuated by the antioxidant probucol. en
dc.format.extent 3539618 bytes
dc.format.mimetype application/pdf
dc.language.iso en_US
dc.subject Cardiotoxicity en
dc.subject Breast en
dc.subject cancer en
dc.subject echocardiography en
dc.subject antioxidant en
dc.subject probucol en
dc.title The cardioprotective effects of probucol against Anthracycline and Trastuzumab mediated cardiotoxicity en
dc.degree.discipline Physiology en
dc.contributor.examiningcommittee Kardami, Elissavet (Physiology); Dixon, Ian (Physiology); Mesaeli, Nasrin (Biochemistry) en
dc.degree.level Master of Science (M.Sc.) en
dc.description.note October 2010 en


Files in this item

This item appears in the following Collection(s)

Show simple item record

View Statistics